<DOC>
	<DOCNO>NCT00002585</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness pyrazoloacridine treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Pyrazoloacridine Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy pyrazoloacridine ( PZA ) administer 3-hour infusion woman metastatic breast cancer . II . Assess qualitative quantitative toxicity PZA schedule . III . Assess response duration survival patient treat agent . OUTLINE : All patient receive intravenous pyrazoloacridine ( PZA ) every 3 week absence progressive disease unacceptable toxicity . Therapy continue respond patient 6 month complete response 1 year , whichever short ; stable patient receive maximum 4 course . The dose increase patient experience minimal toxicity . Patients fail PZA encourage continue therapy cyclophosphamide/doxorubicin/fluorouracil ( CAF ) . All patient follow survival . Prophylactic granulocyte colony-stimulating factor permit . PROJECTED ACCRUAL : Up 20 patient accrue 7-12 month . If 1 response see first 12 evaluable patient , accrual cease .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>NSC 366140</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document breast adenocarcinoma Clinical radiologic evidence metastatic disease require Histologic confirmation recommend evidence equivocal Bidimensionally measurable disease require , i.e . : Lesion clearly define margin physical exam radiologic evaluation 1 diameter great 0.5 cm Lytic bone metastases measurable bone xray/survey Lesion previously irradiate subsequent measurable progression New measurable lesion previously irradiate field The following consider measurable : Unidimensionally measurable lesion Palpable nodal disease measurable CT Masses margin clearly define Lesions diameter less 0.5 cm Bone disease lytic bone disease Pleural effusions ascites Disease identify bone scan History bilateral breast cancer allow No brain metastasis CT require clinically indicate No meningeal carcinomatosis Hormone receptor status : Any status PATIENT CHARACTERISTICS : Age : Over 18 Sex : Women Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 1.5 mg/dL Other : No second malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Adequately treat carcinoma situ cervix Not pregnant nursing Negative pregnancy test require premenopausal woman Appropriate contraception require fertile woman Blood/body fluid analyse determine eligibility physical exam tumor measurement complete within 7 day prior registration ; image study evaluate document measurable disease complete within 4 week prior registration PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy metastatic disease allow At least 4 week since adjuvant chemotherapy Endocrine therapy : Prior hormonal therapy allow At least 4 week since hormonal therapy patient partial complete response recent maneuver Radiotherapy : Prior radiotherapy metastatic disease allow At least 4 week since radiotherapy recover Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>